CCA
GTHX

Catalyst Capital Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Catalyst Capital Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-338
Closed -$6K – 534
2017
Q2 		$6K Buy
+338
New +$5.91K ﹤0.01% 441

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Catalyst Capital Advisors's GTHX Position: Q3 2017 in Review

Catalyst Capital Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2017, closing a stake of 338 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in GTHX in Q2 2017 and held it in 1 quarter. The position peaked at $6K in Q2 2017. 42 funds tracked by Wall St. Rank hold GTHX as of Q3 2017.

  • Catalyst Capital Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Catalyst Capital Advisors sold 338 G1 Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $6K.
  • Catalyst Capital Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Catalyst Capital Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $6K in Q2 2017.
  • 42 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Catalyst Capital Advisors's 13F filing for Q3 2017, filed 8 Nov 2017.